Compounds that inhibit Mcl-1 protein


Ontology type: sgo:Patent     


Patent Info

DATE

2019-12-03T00:00

AUTHORS

BROWN SEAN P , LIZARZABURU MIKE ELIAS , PARAS NICK A , TAYGERLY JOSHUA , VIMOLRATANA MARC , WANG XIANGHONG

ABSTRACT

Provided herein are compounds that are useful intermediates that may used to synthesize myeloid cell leukemia 1 protein (Mcl-1) inhibitors. Also provided are Mcl-1 inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer. More... »

Related SciGraph Publications

  • 2008-12. BCL-2 family antagonists for cancer therapy in NATURE REVIEWS DRUG DISCOVERY
  • 2008-12-16. Mcl-1 is a potential therapeutic target in multiple types of cancer in CELLULAR AND MOLECULAR LIFE SCIENCES
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/03", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/0305", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "name": "BROWN SEAN P", 
            "type": "Person"
          }, 
          {
            "name": "LIZARZABURU MIKE ELIAS", 
            "type": "Person"
          }, 
          {
            "name": "PARAS NICK A", 
            "type": "Person"
          }, 
          {
            "name": "TAYGERLY JOSHUA", 
            "type": "Person"
          }, 
          {
            "name": "VIMOLRATANA MARC", 
            "type": "Person"
          }, 
          {
            "name": "WANG XIANGHONG", 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1038/nrd2658", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1030857223", 
              "https://doi.org/10.1038/nrd2658"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00018-008-8637-6", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1023498818", 
              "https://doi.org/10.1007/s00018-008-8637-6"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2019-12-03T00:00", 
        "description": "

    Provided herein are compounds that are useful intermediates that may used to synthesize myeloid cell leukemia 1 protein (Mcl-1) inhibitors. Also provided are Mcl-1 inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I,

    \n

    \"embedded
    \nand pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.\n

    ", "endDate": "2035-08-28", "id": "sg:patent.US-10494381-B2", "name": "Compounds that inhibit Mcl-1 protein", "recipient": [ { "id": "http://www.grid.ac/institutes/grid.417886.4", "type": "Organization" } ], "sameAs": [ "https://app.dimensions.ai/details/patent/US-10494381-B2" ], "sdDataset": "patents", "sdDatePublished": "2022-09-02T16:21", "sdLicense": "https://scigraph.springernature.com/explorer/license/", "sdPublisher": { "name": "Springer Nature - SN SciGraph project", "type": "Organization" }, "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/patent/patent_25.jsonl", "type": "Patent" } ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/patent.US-10494381-B2'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/patent.US-10494381-B2'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/patent.US-10494381-B2'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/patent.US-10494381-B2'


     

    This table displays all metadata directly associated to this object as RDF triples.

    54 TRIPLES      15 PREDICATES      18 URIs      9 LITERALS      2 BLANK NODES

    Subject Predicate Object
    1 sg:patent.US-10494381-B2 schema:about anzsrc-for:03
    2 anzsrc-for:0305
    3 schema:author N8d4548d04e9448a2a77e14e54ae4c74c
    4 schema:citation sg:pub.10.1007/s00018-008-8637-6
    5 sg:pub.10.1038/nrd2658
    6 schema:datePublished 2019-12-03T00:00
    7 schema:description <p id="p-0001" num="0000">Provided herein are compounds that are useful intermediates that may used to synthesize myeloid cell leukemia 1 protein (Mcl-1) inhibitors. Also provided are Mcl-1 inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I,</p> <p id="p-0002" num="0000"><chemistry id="CHEM-US-00001" num="00001"><img id="EMI-C00001" he="41.74mm" wi="68.75mm" file="US10494381-20191203-C00001.TIF" alt="embedded image" img-content="chem" img-format="tif" orientation="portrait" inline="no"/><attachments><attachment idref="CHEM-US-00001" attachment-type="cdx" file="US10494381-20191203-C00001.CDX"/><attachment idref="CHEM-US-00001" attachment-type="mol" file="US10494381-20191203-C00001.MOL"/></attachments></chemistry><br/> and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer. </p>
    8 schema:endDate 2035-08-28
    9 schema:name Compounds that inhibit Mcl-1 protein
    10 schema:recipient grid-institutes:grid.417886.4
    11 schema:sameAs https://app.dimensions.ai/details/patent/US-10494381-B2
    12 schema:sdDatePublished 2022-09-02T16:21
    13 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    14 schema:sdPublisher N3da25f24a6cd4394b6a17905b1fbcf54
    15 sgo:license sg:explorer/license/
    16 sgo:sdDataset patents
    17 rdf:type sgo:Patent
    18 N10eb97a6d7a244f8a11d2b0596dc8db1 schema:name WANG XIANGHONG
    19 rdf:type schema:Person
    20 N2935fb4997094c3e95a4d4940418654e rdf:first Nc9726345febe4a54af17eee9f4a1d3c1
    21 rdf:rest Ne896b8bf9ae549ef9df9dabebbdbe922
    22 N3da25f24a6cd4394b6a17905b1fbcf54 schema:name Springer Nature - SN SciGraph project
    23 rdf:type schema:Organization
    24 N4efc1c20d94144d59cb22576ec394e0e schema:name TAYGERLY JOSHUA
    25 rdf:type schema:Person
    26 N7b499ff3923c404ea788fb331ef9d476 schema:name VIMOLRATANA MARC
    27 rdf:type schema:Person
    28 N8d4548d04e9448a2a77e14e54ae4c74c rdf:first Nb2934c37247d43bd959b13dc7cae3949
    29 rdf:rest N2935fb4997094c3e95a4d4940418654e
    30 N98ea701a4cbe485b93b3ad611cf72d46 rdf:first N7b499ff3923c404ea788fb331ef9d476
    31 rdf:rest N9e34ea17ceba4fbfadb083fede21fa70
    32 N9e34ea17ceba4fbfadb083fede21fa70 rdf:first N10eb97a6d7a244f8a11d2b0596dc8db1
    33 rdf:rest rdf:nil
    34 Nb2934c37247d43bd959b13dc7cae3949 schema:name BROWN SEAN P
    35 rdf:type schema:Person
    36 Nb746addb2ed04c46aa6b2bfb27773bee schema:name PARAS NICK A
    37 rdf:type schema:Person
    38 Nc9726345febe4a54af17eee9f4a1d3c1 schema:name LIZARZABURU MIKE ELIAS
    39 rdf:type schema:Person
    40 Ne24a1fe694e4420284fe1ea291ea586a rdf:first N4efc1c20d94144d59cb22576ec394e0e
    41 rdf:rest N98ea701a4cbe485b93b3ad611cf72d46
    42 Ne896b8bf9ae549ef9df9dabebbdbe922 rdf:first Nb746addb2ed04c46aa6b2bfb27773bee
    43 rdf:rest Ne24a1fe694e4420284fe1ea291ea586a
    44 anzsrc-for:03 schema:inDefinedTermSet anzsrc-for:
    45 rdf:type schema:DefinedTerm
    46 anzsrc-for:0305 schema:inDefinedTermSet anzsrc-for:
    47 rdf:type schema:DefinedTerm
    48 sg:pub.10.1007/s00018-008-8637-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023498818
    49 https://doi.org/10.1007/s00018-008-8637-6
    50 rdf:type schema:CreativeWork
    51 sg:pub.10.1038/nrd2658 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030857223
    52 https://doi.org/10.1038/nrd2658
    53 rdf:type schema:CreativeWork
    54 grid-institutes:grid.417886.4 schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...